There were 2,410 press releases posted in the last 24 hours and 359,836 in the last 365 days.

SAGE to Report Third Quarter 2015 Financial Results on Thursday, November 5, 2015

CAMBRIDGE, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE) today announced that the company will host a conference call and live webcast on Thursday, November 5, 2015 at 4:30 p.m. ET to report its financial results for the third quarter 2015 and discuss recent business updates.

The live webcast can be accessed on the investor page of SAGE's website at investor.sagerx.com. The conference call can be accessed by dialing 1-866- 450-8683 (toll-free domestic) or 1-281-542-4847 (international) and using the conference ID 71025439. A replay of the webcast will be available on SAGE's website approximately two hours after the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics (NASDAQ:SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. SAGE has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. SAGE's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. SAGE is developing its next generation modulators, including SAGE-217 and SAGE-689, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.

Investor Contact:
Paul Cox, Sage Therapeutics
paul.cox@sagerx.com
617-299-8377

Media Contact:
Dan Budwick, Pure Communications
dan@purecommunicationsinc.com
973-271-6085

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.